Stay updated with breaking news from Big Effect Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second...
Press release content from Business Wire. The AP news staff was not involved in its creation.
Humanigen, Inc. has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases' ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus... | July 13, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation. Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update March 10, 2021 GMT BURLINGAME, Calif.--(BUSINESS WIRE)--Mar 10, 2021-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today reported financial results for the year ending December 31, 2020 and announced objectives for 2021. “...